Lake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Lake Street analyst Thomas Flaten maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $50 to $40.
Lake Street analyst Thomas Flaten maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $50 to $40.
